Cannabinoids in medicine
For many decades, the psychoactive cannabis ingredient tetrahydrocannabinol (THC) has been in the foreground of research, as it can induce psychotropic effects when inhaled. THC was the cannabinoid whose therapeutic potential was first recognized and further researched by physicians and scientists. However, this research has been hampered for decades by the stigmatization of cannabis as a drug with psychotropic effects.
It was not until the beginning of the new millennium that more and more interest worldwide in cannabinoids as potent active ingredients for the treatment of serious, previously untreatable, symptoms led to intensified research into both Dronabinol and cannabidiol. The aim of this intensified research is to become a valuable active ingredient in adjuvant therapy of different indications.
As a pure substance for pharmaceutical or medical purposes, tetrahydrocannabinol (THC) is usually referred to by its international nonproprietary name dronabinol. The active ingredient THC is the only cannabinoid in Germany that got the regulatory requirements since 1998 and can be prescribed as a narcotic. For this purpose it is usually dispensed by pharmacies as pharmacy compounded products in the form of oily drops or capsules.
Only two years later, in 2000, dronabinol produced synthetically by THC Pharm in Germany began to be offered as an active ingredient available by prescription. After another two years, naturally prepared dronabinol from cannabis flowers was brought onto the market by Bionorica ethics. The narcotic dronabinol is mainly used for the supplementary treatment of severe symptoms of critically ill patients that do not respond to other treatments (refractory conditions).
Since dronabinol is subject to the narcotics law, any further information on this substance must be restricted for legal reasons to specialists in the trade and industry as well as doctors and pharmacists, and may not be presented to the public. Thank you for your understanding.